GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tibet Weixinkang Pharmaceutical Co 603676.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.24

0.00%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tibet Weixinkang Pharmaceutical Co

Its shares trade on Shanghai under the ticker 603676.SS. It has been listed since 21 July 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.14bn and net income of CN¥232.9m. At that date it held total assets of CN¥1.87bn and shareholders' equity of CN¥1.48bn.

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company is headquartered in Lhasa, Xizang. The company went IPO on 2017-07-21. The firm's main products include injection of complex vitamins, injection of potassium aspartate magnesium, sucrose iron injection and potassium aspartate injection. The firm is also engaged in the production and sales of liver protection drugs and antibiotics products. The firm mainly distributes its products in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Jul 2017
Employees
656

Leadership

Pay as last reported

  • Mr. Yong ZhangChairman of the Board, General Manager
  • Ms. Xiaoping XiongChief Financial Officer, Secretary of the Board
  • Mr. Feng LiuDeputy General Manager, Director
  • Mr. Hong ZhangDeputy General Manager, Director
  • Mr. Zizhong WengDeputy General Manager
  • Mr. Xiaoquan WenDirector
  • Mr. Xuan PanIndependent Director
  • Mr. Xiping ZhuIndependent Director
  • Mr. Xiaodong ZouIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tibet Weixinkang Pharmaceutical Co Ltd employs 656 full-time staff members for its operations.
  • The company engages in research and development of pharmaceutical products in Lhasa.
  • Main products include injection of complex vitamins and sucrose iron injection.

Weaknesses

  • The firm mainly distributes its products in the domestic market only.
  • Revenue sources are limited to specific injection and antibiotic product lines.
  • Operations are concentrated in Lhasa, Xizang, limiting geographic diversity.

Opportunities

  • Expansion into liver protection drugs could increase market share significantly.
  • Growing demand for antibiotics products offers potential revenue growth opportunities.
  • Investing in potassium aspartate magnesium injection may attract new customers.

Threats

  • Dependence on the domestic market exposes the firm to local economic shifts.
  • Regulatory changes in the Health Care sector could impact production costs.
  • Competition in the Pharmaceuticals industry may reduce profit margins for injections.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.